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ABSTRACT
Poly(ADP-ribose) polymerase 1 (PARP1) synthesizes
poly(ADP-ribose) (PAR) using nicotinamide adenine
dinucleotide (NAD) as a substrate. Despite intensive
research on the cellular functions of PARP1, the
molecular mechanism of PAR formation has not
been comprehensively understood. In this study,
we elucidate the molecular mechanisms of
poly(ADP-ribosyl)ation and identify PAR acceptor
sites. Generation of different chimera proteins
revealed that the amino-terminal domains of
PARP1, PARP2 and PARP3 cooperate tightly with
their corresponding catalytic domains. The DNA-
dependent interaction between the amino-terminal
DNA-binding domain and the catalytic domain of
PARP1 increased Vmax and decreased the Km for
NAD. Furthermore, we show that glutamic acid resi-
dues in the auto-modification domain of PARP1
are not required for PAR formation. Instead, we
identify individual lysine residues as acceptor sites
for ADP-ribosylation. Together, our findings provide
novel mechanistic insights into PAR synthesis with
significant relevance for the different biological
functions of PARP family members.
INTRODUCTION
Poly(ADP-ribose) polymerases (PARPs) use nicotinamide
adenine dinucleotide (NAD) as substrate to synthesize
poly(ADP-ribose) (PAR) (1). On the cellular level,
PAR formation has been implicated in a wide range
of processes, such as maintenance of genomic stability,
transcriptional regulation, energy metabolism and cell
death (2).
PARP1 was the ﬁrst protein described to catalyze
PAR formation in response to mitogenic stimuli or geno-
toxic stress (3–7). It contains three functionally distinct
domains: an amino-terminal DNA-binding domain
(DBD), an auto-modiﬁcation domain (AD) and a car-
boxyl-terminal PARP homology domain that includes
the catalytic domain (CAT) responsible for PAR forma-
tion (8). The DBD extends from the initiator methionine
to threonine 373 in human PARP1. It contains two struc-
turally and functionally unique zinc ﬁngers (FI: aa, amino
acid, 11–89; FII: aa 115–199) (2,9). Recently, a third
and so far unrecognized zinc-binding motif was discovered
(FIII: aa 233–373) (10,11). The DBD also contains
a bipartite nuclear localization signal (NLS) of the form
KRK-X(11)-KKKSKK (aa 207–226) that targets PARP1
to the nucleus (12). The PARP1 zinc ﬁngers FI and FII are
thought to recognize altered structures in DNA rather
than particular sequences and have also been reported to
be involved in protein–protein interactions (13). PARP1
strongly associates with DNA single and double strand
breaks generated either directly by DNA damage or indi-
rectly by the enzymatic excision of damaged bases during
DNA repair processes (2,9). Several studies indicate that
the ﬁrst zinc ﬁnger is required for PARP1 activation by
both DNA single and double strand breaks, whereas the
second zinc ﬁnger may exclusively act as a DNA single
strand break sensor (2,9).
The AD of PARP1 is located in the central region of
the enzyme, between residues 373 and 525 of human
PARP1 (14,15). It was identiﬁed as the domain containing
acceptor amino acids for the covalent attachment of PAR
(16). In addition, several recent studies identiﬁed a weak
leucine-zipper motif in the amino-terminal region of the
AD, which suggests that this motif might be involved in
homo- and/or hetero-dimerization (9). The AD of PARP1
also comprises a breast cancer 1 protein (BRCA1)
C-terminus (BRCT) domain (from aa 386 to 464 in
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human PARP1) as well as an unstructured loop that
connects the AD with the PARP homology domain.
PARP1 contains an 80–90 amino acid long trypto-
phane-, glycine-, arginine-rich (WGR) domain carboxyl
terminal of the AD. The WGR domain is named after
the most conserved central motif of tryptophane (W),
glycine (G), arginine (R) residues and may represent a
nucleic-acid-binding domain (2). This region of PARP1
has not been extensively characterized and its function is
still unknown. The CAT has been suggested to catalyze at
least three diﬀerent enzymatic reactions: the attachment of
the ﬁrst ADP-ribose moiety onto an acceptor amino acid
(initiation reaction), the addition of further ADP-ribose
units onto already existing ones (elongation reaction)
and the generation of branching points (branching reac-
tion) (8). The active site is formed by a phylogenetically
well-conserved sequence of 50 residues (aa 859–908
of hPARP1). This ‘PARP signature’ contains the NAD
acceptor sites and critical residues involved in the initia-
tion, elongation and branching of PAR.
Like PARP1, both PARP2 and PARP3 also contain a
WGR as well as a CAT (16). PARP2 and PARP3 lack,
however, most motifs present in the amino-terminal
half of PARP1. Neither zinc-binding motifs nor leucine-
zippers or BRCT domains have been described for PARP2
or PARP3. PARP2 contains an amino-terminal SAP/SAF
motif/module [named after scaﬀold-associated protein/
scaﬀold-associated factor SAF-A/B, Acinus and PIAS;
(17)] and a eukaryotic module proposed to be involved
in sequence- or structure-speciﬁc DNA and RNA binding
(18). Furthermore, PARP2 contains an amino-terminal
NLS which targets the protein to the nucleus. PARP3 is
the least studied and smallest PARP identiﬁed so far (19).
The protein domain structure of PARP3 is very similar to
that of PARP2, featuring a small putative DBD consisting
of only 54 residues and apparently containing a targeting
motif that is suﬃcient to localize the enzyme to the cen-
trosome (19,20).
Attempts to obtain structural information on the
full-length proteins PARP1, PARP2 and PARP3 by
X-ray crystallography or by nuclear magnetic resonance
(NMR) have not been successful up to now. The 3D struc-
tures of single domains, however, have been solved and
allow for a structure-based comparison of diﬀerent PARP
family members (8,21) (PDB: 1A26, 1GS0 and 2PA9).
Although the amino acid identity between PARP1 and
PARP2 or PARP3 is only moderate (40% and 32% in
the CAT, respectively), the overall structure of the CATs
of these three proteins is nearly identical. This conserva-
tion suggests, in general, similar capabilities to generate
PAR. Both PARP1 and PARP2 have been shown to syn-
thesize very complex branched polymers at least in vitro
(2). The enzymatic activity of PARP3 and its isoforms has
not yet been investigated in detail.
An unresolved issue regarding the mechanism of
poly(ADP-ribosyl)ation is how DNA binding in the
amino-terminal DBD triggers enzyme activation in the
carboxyl-terminal CAT and how the diﬀerent domains
of the diﬀerent PARPs are coordinated during this pro-
cess. Furthermore, earlier studies suggested that the auto-
modiﬁcation activity targets between 4 and 28 acceptor
residues located in the AD and in the DBD of PARP1
(14,22,23). For histone H1, a major target for trans-
poly(ADP-ribosyl)ation by PARP1, glutamic acid residues
have been described to function as acceptors for PAR
(24). This, together with the reported chemical similarity
between the ADP-ribose-PARP1 linkage and carboxyl
esters in mono-ADP-riboslyated histones (23), led to
the hypothesis that multiple glutamic acid residues present
in the AD of PARP1 might function as acceptor sites
for auto-poly(ADP-ribosyl)ation (16). However, despite
intensive research during the last 40 years, the acceptor
amino acids in PARP1 have not been conﬁrmed by muta-
tional studies.
Here, we comprehensively analyze PAR formation by
PARP1, PARP2 and PARP3 and ﬁnd a close cooperativ-
ity between the amino-terminal portions of the proteins
and their corresponding CATs. We deﬁne the DBD
(aa 1–373) and the WGR/CAT domain (aa 533–1014)
as the minimal domains of PARP1 required for PAR
formation. The DNA-dependent interaction between the
DBD and the CAT increased Vmax and decreased the Km
for NAD. Furthermore, by amino-acid substitutions,
we establish that glutamic acid residues within the AD
are not required for PAR formation and thus do not func-
tion as acceptor amino acids for PAR. Instead, we identify
lysine residues within the AD of PARP1 as acceptor sites
for ADP-ribosylation.
MATERIALS AND METHODS
Chemicals and antibodies
3H-NAD and protein A sepharose were purchased from
GE Healthcare and 32P-NAD was from PerkinElmer.
NAD was obtained from Sigma-Aldrich. Anti-PAR anti-
body LP96-10 was from Alexis Biochemicals or Becton
Dickinson, anti-PARP1cat antibody H250 from Santa
Cruz Biotechnology and anti-haemagglutinin (HA) anti-
body 16B12 from Covance.
Plasmids
The baculovirus expression vectors pQE-TriSystem
(Qiagen) and BacPak8 (Clontech) were used for the
expression of recombinant proteins in Sf21 insect cells as
described previously (25,26).
Cloning, expression and purification of recombinant
proteins
Wild-type hPARP1 (NCBI ID: BC037545), hPARP2
(NCBI ID: NM_001042618) and hPARP3 (NCBI ID:
BC014260) were cloned and expressed as carboxyl-
terminal His-tagged proteins. PARP family chimera were
generated by overlapping polymerase chain reaction
(PCR) at the position corresponding to amino acid 533
in hPARP1 and expressed as carboxyl-terminal His-
tagged proteins. Protein fragments and deletion mutants
were generated by PCR and expressed as carboxyl-
terminal His-tagged proteins as described before (25,26).
Amino-acid substitutions were introduced by site-
directed PCR-based mutagenesis and mutant proteins
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were expressed as described before (25,26). All recom-
binant proteins were puriﬁed by one step aﬃnity chro-
matography using ProBond resin according to the
manufacturer’s recommendations (Invitrogen). Expres-
sion and puriﬁcation of all recombinant proteins was
analyzed by SDS–PAGE followed by coomassie staining.
For the stacking gel a 4.5% acrylamide-bis solution
[37.5:1, 40% (w/v), Serva] and for the separating gel a
10–12.5% acrylamide-bis solution was used.
PAR formation assays
3H-NAD time course experiments. One hundred pico-
moles recombinant puriﬁed enzyme and 5 mg of protein
fragments in PAR reaction buﬀer (50mM Tris–HCl
pH 8.0, 4mM MgCl2, 250 mM DTT, 1 mg/ml pepstatin,
1 mg/ml bestatin, 1 mg/ml leupeptin) in the presence of
50 pmol annealed double-stranded oligomer (50-GGAAT
TCC-30) were supplemented with 3H-NAD to a ﬁnal con-
centration of 400 mM. PAR formation was allowed for 1,
3, 5, 15 and 60min at 308C. Reactions were stopped by
addition of ice-cold 10% TCA/2% Na4P2O7. Polymers
were precipitated for 10min on ice and then applied
onto ﬁlter papers. Counts per minute were obtained by
liquid scintillation counting. For the determination of
Vmax and Km, initial reaction velocities (V0) were obtained
by measuring PAR levels generated after 0, 1, 3 and 5min
incubation at diﬀerent 3H-NAD concentrations and using
the GraphPad Prism software for nonlinear regression
analysis assuming a one-site binding model. Vmax and
Km were calculated from V0 according to Michaelis–
Menten.
Anti-PAR western blot. Unless otherwise stated, 10 pmol
recombinant puriﬁed enzyme and 0.5mg of protein frag-
ments in PAR reaction buﬀer in the presence of 5 pmol
annealed double-stranded oligomer (50-GGAATTCC-30)
were supplemented with NAD to a ﬁnal concentration
of 400 mM. PAR formation was allowed for 5min at
308C. Reactions were stopped by addition of SDS–
PAGE loading buﬀer and boiling for 5min at 958C.
Samples were subjected to SDS–PAGE followed by anti-
PAR western blot.
32P-NAD auto-modification. Unless otherwise stated,
10 pmol recombinant puriﬁed enzyme and 0.5mg of pro-
tein fragments in PAR reaction buﬀer in the presence of
5 pmol annealed double-stranded oligomer (50-GGAATT
CC-30) were supplemented with 32P-NAD to a ﬁnal con-
centration of 100 nM. Auto-modiﬁcation was allowed for
10 s at 308C. Reactions were stopped by addition of SDS–
PAGE loading buﬀer and boiling for 5min at 958C.
Samples were subjected to SDS–PAGE followed by detec-
tion of auto-modiﬁcation by autoradiography.
PAR detection by silver staining. Following synthesis
of PAR as for western blot analysis, PAR chains were
puriﬁed and separated by modiﬁed DNA sequencing gel
electrophoresis as described by Fahrer et al. (27).
In vitro co-immunoprecipitation. Ten picomoles recombi-
nant puriﬁed enzyme and 0.5mg of protein fragments were
incubated for 5min at 308C in Co-IP buﬀer (50mM Tris–
HCl pH 8.0, 100mM NaCl, 4mM MgCl2, 0.2% NP-40,
250 mM DTT, 1 mg/ml pepstatin, 1 mg/ml bestatin, 1 mg/ml
leupeptin) in the absence or presence of 5 pmol annealed
double-stranded oligomer (50-GGAATTCC-30). The CAT
of PARP1 was allowed to bind to the anti-PARP1cat anti-
body for 1 h at 48C. Protein A sepharose was added and
samples were incubated for another 2 h at 48C. Samples
were washed three times for 5min in Co-IP buﬀer contain-
ing 300mM NaCl before being subjected to SDS–PAGE
followed by western blot.
RESULTS
Purified full-length human PARP1 and PARP2 are
enzymatically active
In order to gain detailed insights into the mechanism of
PAR formation by diﬀerent PARP family members, we
expressed and puriﬁed full-length human PARP1, PARP2
and PARP3 using the baculovirus expression system
(Figure 1A and B). PARP3 showed a slower migration
velocity than predicted in SDS–PAGE, possibly due to
the high content of hydrophobic amino acids in the
CAT. To measure PAR formation, the puriﬁed proteins
were incubated for diﬀerent time periods with 400 mM
tritium-labeled NAD in the presence of double strand
break mimicking DNA. Reaction products were precipi-
tated by trichloroacetic acid (TCA) before they were ana-
lyzed using a beta counter. PARP1 generated PAR in a
time-dependent manner (Figure 1C, left panel). PARP2
also synthesized PAR in a time-dependent manner, how-
ever, not as eﬃciently as PARP1 (Figure 1C, middle
panel). The reduced amount of product formed by
PARP2 most probably represents a quantitative rather
than a qualitative diﬀerence, since the length distribution
of PAR chains formed by PARP2 was comparable to
the length distribution of PAR formed by PARP1
(Supplementary Figure 4B). Human PARP3 did not pro-
duce detectable amounts of PAR under the tested condi-
tions (Figure 1C, right panel).
Assuming that mono(ADP-ribosyl)ation preceeds PAR
formation, we assessed the auto-modiﬁcation of the three
proteins after 10 s incubation with 100 nM radiolabeled
NAD (Figure 1D). The short incubation period and
the low concentration of NAD were chosen to pre-
vent polymer formation. The discrete bands observed
using this approach indeed suggest that under these con-
ditions mostly mono(ADP-ribosyl)ation occurred. In
line with the time-course experiments, PARP1 and
PARP2 were able to auto-modify themselves in an
NAD- and DNA-dependent manner while PARP3 was
not (Figure 1D).
PARP1 synthesized increasing PAR levels in a time-
and DNA-dependent manner detected also by western
blot and vacuum slot blot using 400 mM NAD
(Supplementary Figure 1A and B). PAR formation
after 5min incubation with 400 mM NAD caused a pro-
nounced shift of the coomassie blue-stained proteins in
the denaturing gel due to a severely reduced migration
velocity of the poly(ADP-ribosyl)ated proteins when
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compared to unmodiﬁed proteins (Supplementary
Figure 1C). The observed basal activity of PARP1 in
the absence of DNA can be explained either by a con-
tamination with DNA or by the intrinsic DNA-inde-
pendent activity of the CAT as described by Simonin
et al. (28). Analysis of PAR formation by silver stain-
ing after modiﬁed DNA sequencing gel electrophoresis
conﬁrmed PAR formation by PARP1 and PARP2
and no PAR formation by PARP3 (Supplementary
Figure 4B).
Figure 1. Puriﬁed full-length human PARP1 and PARP2 are enzymatically active. (A) Domain organization of human PARP1, PARP2 and PARP3.
Letters A–F indicate domain nomenclature of PARP1 and numbers indicate amino acid positions. (B) Purity of PARP family members after one step
aﬃnity chromatography. One microgram of each recombinant, puriﬁed protein was used for SDS–PAGE followed by coomassie staining. (C) Time
course of PAR formation by diﬀerent PARP family members. 3H-NAD incorporation into TCA-precipitable polymers was determined by scintil-
lation counts. Substrate concentration: 400mM 3H-NAD. Reactions were performed in triplicates, error bars represent standard deviations. (D) Auto-
modiﬁcation of diﬀerent PARP family members detected by autoradiography. Substrate concentration: 100 nM 32P-NAD. Molecular size markers in
kilo Daltons are indicated.
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The carboxyl-terminal domains of PARP1, PARP2 and
PARP3 cannot compensate for each other
Next, we investigated the crosstalk between the diﬀerent
amino-terminal domains of PARP1, PARP2 and PARP3
with their carboxyl-terminal domains (i.e. WGR/CAT).
Therefore, we generated chimera proteins by replacing
the WGR/CAT domain of PARP1 with the WGR/CAT
domain of PARP2 or PARP3 [named chimera PARP1-2
(aa 1–532 of PARP1 fused to aa 81–570 of PARP2) or
chimera PARP1-3 (aa 1–532 of PARP1 fused to aa 48–533
of PARP3)], respectively (Figure 2A and B). We analyzed
PAR formation by these proteins and found that replacing
the WGR/CAT domain of PARP1 by the one of PARP2
(i.e. chimera PARP1-2) resulted in an active enzyme that
showed roughly similar PAR formation in time course
experiments as PARP2 (Figure 2C, middle panel).
Replacement of the WGR/CAT domain of PARP1 by
that of PARP3 (i.e. chimera PARP1-3) resulted in an
enzyme that did not produce detectable amounts of
PAR under the tested conditions (Figure 2C, right panel
and Supplementary Figure 1D). In line with these ﬁndings,
chimera PARP1-2 was able to auto-modify itself whereas
chimera PARP1-3 was not (Figure 2D). Together
these results suggest that the WGR/CAT domains of the
investigated PARP proteins cannot compensate for each
other. The WGR/CAT domains cooperate tightly with
their corresponding amino-terminal domains and limit
poly(ADP-ribosyl)ation capacity and the ability for
auto-modiﬁcation, despite high levels of structural similar-
ity between the CATs (see Supplementary Figure 2A).
The carboxyl-terminal domain of PARP1 is not activated
by the amino-terminal domains of PARP2 or PARP3
In a second set of chimera proteins we fused the WGR/
CAT domain of PARP1 to the amino-terminal domains of
PARP2 or PARP3, or deleted the amino-terminal domain
Figure 2. The carboxyl-terminal domains of PARP1, PARP2 and PARP3 cannot compensate for each other. (A) Domain organization of chimera
PARP1-2 and chimera PARP1-3. (B) Purity of chimera PARP1-2 and chimera PARP1-3 after one-step aﬃnity chromatography. One microgram of
each recombinant, puriﬁed protein was used for SDS–PAGE followed by coomassie staining. (C) Time course of PAR formation by PARP1, chimera
PARP1-2 and chimera PARP1-3 as in Figure 1C. (D) Auto-modiﬁcation of PARP1, chimera PARP1-2 and chimera PARP1-3 detected by auto-
radiography as in Figure 1D. Molecular size markers in kilo Daltons are indicated.
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of PARP1 [named chimera PARP2-1 (aa 1–80 of PARP2
fused to aa 533–1014 of PARP1), chimera PARP3-1
(aa 1–47 of PARP3 fused to aa 533–1014 of PARP1)
or PARPs-1 (aa 533–1014 of PARP1)], respectively
(Figure 3A and B). Analysis of these proteins revealed
that chimera PARP2-1, chimera PARP3-1 and PARPs-1
did not generate detectable levels of PAR (Figure 3C
and Supplementary Figure 1E). Furthermore, no auto-
modiﬁcation of the three proteins was observed under
the tested conditions (Figure 3D). These results indicate
that the WGR/CAT domain of PARP1 is only stimulated
by its corresponding amino-terminal domain, but not by
the amino-terminal domains of PARP2 or PARP3.
The DBD of PARP1 is sufficient to stimulate its
WGR/CAT domain
To further investigate the cooperativity between the
amino-terminal domain of PARP1 and its WGR/CAT
Figure 3. The carboxyl-terminal domain of PARP1 is not activated by the amino-terminal domains of PARP2 or PARP3. (A) Domain organization
of chimera PARP2-1, chimera PARP3-1 and PARPs-1. (B) Purity of chimera PARP2-1, chimera PARP3-1 and PARPs-1 after one-step aﬃnity
chromatography. One microgram of each recombinant, puriﬁed protein was used for SDS–PAGE followed by coomassie staining. (C) Time course of
PAR formation by chimera PARP2-1, chimera PARP3-1 and PARPs-1 as in Figure 1C. (D) Auto-modiﬁcation of PARP1 (ctr.), chimera PARP2-1,
chimera PARP3-1 and PARPs-1 detected by autoradiography as in Figure 1D. Molecular size markers in kilo Daltons are indicated.
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domain, the inactive chimera PARP2-1 was co-incubated
with the PARP1 E988K mutant, which lacks the ability
to generate PAR. Surprisingly, co-incubation of chimera
PARP2-1 with PARP1 E988K strongly induced PAR
synthesis, suggesting that PARP1 E988K was able to stim-
ulate the WGR/CAT domain of chimera PARP2-1
(Figure 4A). To map the minimal domain of PARP1,
which was able to stimulate the WGR/CAT domain of
chimera PARP2-1, we expressed and puriﬁed diﬀerent
fragments of PARP1 covering all domains from A to F
(see Figure 1A). Analysis of PAR synthesis by western
blot upon co-incubation of chimera PARP2-1 with these
fragments revealed that the DBD of PARP1 comprising
amino acid 1–373 was the only fragment able to stimulate
chimera PARP2-1 (Figure 4B). Further dissection of the
DBD revealed that only the complete and undisrupted
DBD from amino acid 1 to 373 containing FI, FII and
FIII was able to stimulate chimera PARP2-1 (Figure 4C).
The stimulation of chimera PARP2-1 by the DBD was
salt resistant up to 300mM NaCl (Supplementary
Figure 3B, left panel).
To further assess the speciﬁcity of the observed stimula-
tion, the DBD was incubated with diﬀerent proteins (chi-
mera PARP2-1, chimera PARP3-1, PARPs-1 and PARP1
656–1014) and the time course of PAR formation
was analyzed using tritium-labeled NAD. Of note, besides
chimera PARP2-1, only chimera PARP3-1 and PARPs-1,
but neither the CAT of PARP1 nor full-length PARP2,
PARP3, chimera PARP1-2 or chimera PARP1-3, were
stimulated by the DBD of PARP1 (Figure 4D and
Supplementary Figure 4A and C). Analysis of PAR for-
mation by silver staining after polymer separation using
modiﬁed DNA sequencing gel electrophoresis conﬁrmed
that the observed stimulation in the time course experi-
ments correlated with the synthesis of PAR containing 1
to more than at least 50 ADP-ribose units (Supplementary
Figure 4B).
The stimulation of chimera PARP2-1 by the DBD was
strongly dependent on DNA (Figure 4E, left panel), which
suggests that DNA tightly regulates the interaction neces-
sary for the activation of the CAT. Furthermore, our
observation that PARPs-1 but not PARP1 656–1014
together with the DBD was able to generate PAR indi-
cates that the WGR domain of PARP1 is absolutely essen-
tial for enzymatic activity.
Since chimera PARP2-1 does not exist physiologically,
PAR synthesis by a PARP1 DBD deletion mutant
(aa 373–1014) co-incubated with the DBD was analyzed.
Interestingly, the DBD was able to stimulate PARP1
373–1014 in a DNA-dependent manner and comparable
to PARP2-1 (Figure 4E, right panel and Supplementary
Figure 3B, right panel), suggesting that the observed stim-
ulation of PARP2-1 by the DBD represents a physiolog-
ical regulatory mechanism in the PARP1 full-length
context.
The DBD of PARP1 interacts with its CAT domain
The results described above suggest that the DBD of
PARP1 interacts with the CAT and/or the WGR
domain to stimulate PAR synthesis by the CAT. To test
this hypothesis experimentally, in vitro co-immunoprecipi-
tation assays were performed with puriﬁed proteins
and fragments. The complete DBD (aa 1–373), but not
aa 1–214 alone, speciﬁcally bound to chimera PARP2-1
in a manner that was stabilized by DNA (Figure 4F).
Similarly, the DBD also bound to PARP1 373–1014,
and this interaction was enhanced by DNA (Figure 4G,
left panel). Interestingly, the CAT domain of PARP1
without the WGR (aa 656–1014) was suﬃcient for the
DNA-dependent interaction with the DBD (Figure 4G,
right panel). Since PAR formation was only observed
when combining the DBD with PARPs-1 (expressing
WGR/CAT) but not with the CAT domain of PARP1
alone (Figure 4D and Supplementary Figure 4A), we con-
clude that an intact DBD (aa 1–373) interacts with the
CAT in a DNA-dependent manner and that the WGR
domain is additionally required to allow PAR formation.
The DBD bound to DNA activates the CAT by increasing
Vmax and decreasing Km
Next, we determined the enzymatic parameters of chimera
PARP2-1 stimulated by the PARP1 DBD in the absence
or presence of DNA. We measured the incorporation of
tritium-labeled NAD into TCA-precipitable polymers at
early reaction time points and obtained initial reaction
velocities (V0) for diﬀerent substrate concentrations by
nonlinear regression analysis assuming one substrate-
binding site. In the absence of the DBD, chimera
PARP2-1 did not generate detectable levels of PAR inde-
pendent of the addition of DNA (Table 1, second and
third column), thus conﬁrming our previous results. In
the presence of the DBD, PAR generation was strongly
dependent on DNA. Without DNA, the obtained PAR
levels were low, but still allowed for curve ﬁtting and cal-
culation of Vmax and Km values (Table 1, fourth column).
Addition of DNA increased the maximum reaction veloc-
ity Vmax about 4-fold and reduced Km 8-fold (Table 1,
compare ﬁfth to fourth column). The reaction eﬃciency
Kcat/Km was thereby increased by more than 30-fold.
DNA could thus be considered a V+K-type activator,
aﬀecting both turnover rate and substrate aﬃnity.
Remarkably, the enzymatic parameters obtained for chi-
mera PARP2-1 together with the PARP1 DBD closely
match the values reported for full-length PARP1
(Table 1, compare ﬁfth to ﬁrst column). Together, these
results provide evidence that DNA containing double
strand breaks is recognized and bound by the DBD of
PARP1, which subsequently binds to the CAT domain
to induce structural changes within the catalytic cleft
in order to increase the aﬃnity for NAD and stabilize
reaction intermediates.
PARP1 forms a catalytic dimer which requires at least
one functional FI and FIII domain for activity
The CAT of PARP1 was previously described to dimerize
(29). To investigate whether our puriﬁed proteins were also
able to form dimers, the enzymatic activity of full-length
PARP1 was assessed by western blot analysis after
co-incubation with diﬀerent molar ratios of two catalyti-
cally inactive PARP1 mutants (E988K or M890V/D899N,
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Figure 4. The DBD of PARP1 interacts with and is suﬃcient to stimulate its WGR/CAT domain. (A) PAR formation by chimera PARP2-1
co-incubated with catalytically inactive PARP1 E988K. PAR was detected by western blot using anti-PAR antibody LP96-10. Substrate concentra-
tion: 400mM NAD. (B) PAR formation by chimera PARP2-1 co-incubated with the indicated fragments of PARP1 or with PARP1 E988K. (C) PAR
formation of chimera PARP2-1 co-incubated with the indicated fragments or combination of fragments of PARP1. (D) Time course of PAR
formation by chimera PARP2-1, chimera PARP3-1, PARPs-1 and PARP1 656–1014 in the absence or presence of fragment 1–373 as in
Figure 1C. Black without fragment 1–373 and grey with fragment 1–373. (E) PAR formation of chimera PARP2-1 or PARP1 373–1014 co-incubated
with fragment 1–373 in the absence or presence of DNA. (F) In vitro interaction between chimera PARP2-1 and 1–373. Chimera PARP2-1 was
bound to protein A sepharose using an antibody against the CAT of PARP1 (a-PARP1cat) and was then incubated with HA-tagged fragment 1–373
or 1–214 in the absence or presence of DNA. HA-tagged fragments were detected by western blot. PARP1cat antibody coupled to beads without
chimera PARP2-1 served as control (ctr.). (G) In vitro interaction between PARP1 373–1014 or 656–1014 with 1–373. Experiments were performed as
described in (F). Molecular size markers in kilo Daltons and the border between stacking and separating gel (asterisk) are indicated.
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respectively) (Supplementary Figure 3A). A molar ratio
of 1:5 (wt:mutant) severely reduced PAR formation
(Figure 5B), suggesting that the diﬀerent proteins are
indeed able to form dimers and to regulate each other.
We showed earlier that only the full-length DBD was
able to stimulate chimera PARP2-1 (Figure 4). This ﬁnding
suggests that disruption of the DBD of PARP1 by deleting
one of the DBD sub-domains would render the protein
inactive due to lost activation of the CAT. Deletion
of the regions containing zinc ﬁnger FI (FI, aa 1–111)
or zinc-binding domain FIII (FIII, aa 279–333) indeed
rendered PARP1 inactive, while a mutant lacking FII
(FII, aa 117–201) was still able to synthesize PAR as
examined by western blot analysis (Figure 5A and C).
Thus, the presence of FI and FIII is required for enzy-
matic activity, while neither FII nor the spacing between
FI and FIII seem to be critical for PAR formation.
Surprisingly, co-incubation of the two inactive mutants
FI and FIII fully restored activity, suggesting
that the two proteins can interact and that the lack of the
critical domains containing FI and FIII could be inter-
molecularly complemented to form a functional active
dimer (Figure 5D). In line with this ﬁnding, the
mutants FI and FIII could also be complemented by
co-incubation with the catalytically inactive PARP1
mutants E988K and M890V/D899N or with the DBD
alone (Figure 5E).
The WGR domain is vital for enzymatic activity
We showed that the WGR domain is required for enzy-
matic activity of PARP1 (Figure 4). A PARP1 deletion
mutant lacking the WGR domain (WGR, aa 525–656)
was indeed not able to generate PAR (Figure 5F).
Similarly, a PARP2 deletion mutant lacking the WGR
domain was also inactive (data not shown), suggesting
that the so far uncharacterized WGR domain of PARP
family members is absolutely required for the enzymatic
activity. Importantly, the PARP1 WGR mutant could
functionally complement the two PARP1 mutants
FI and FIII by providing its DBD (Figure 5G).
Co-incubation of the PARP1 WGR mutant with the
catalytically inactive PARP1 mutants E988K and
M890V/D899N, both possessing a functional WGR, how-
ever, did not restore enzymatic activity (Figure 5G). Thus,
the PARP1 DBD and the CAT can be regarded as inde-
pendent and ﬂexible protein units in a catalytic dimer,
whereas the WGR domain is functionally tightly asso-
ciated with and required for the activation of the CAT.
Glutamic acid residues in the AD of PARP1
are not modified
It is widely believed that multiple glutamic acid residues
within the AD of PARP1 serve as acceptor sites for the
covalent attachment of PAR (16). To our knowledge,
however, this assumption has so far not been conﬁrmed
by amino acid substitutions. Therefore, we decided to test
whether glutamic acid residues within the AD of PARP1
are required for the catalytic activity of the enzyme and
function as acceptors for PAR. First, we deleted the
BRCT domain as part of the AD (Figure 6A). A
PARP1 BRCT mutant was as active as its wild-type
counterpart with regard to auto-modiﬁcation (Figure 6B,
ﬁrst four lanes) and PAR formation (Supplementary
Figure 5A, left panel). Next, in the context of the
PARP1 BRCT mutant, we additionally mutated all
eight glutamic acid residues in the remaining auto-
modiﬁcation loop between amino acids 484 and 557 to
glutamine (BRCT/E) (Figure 6A). Surprisingly, these
substitutions also did not reduce auto-modiﬁcation
(Figure 6B, last two lanes) or PAR formation
(Supplementary Figure 5A, right panel). These results
strongly indicate that glutamic acid residues within the
AD of PARP1 are not required for enzymatic activity
and are unlikely to serve as acceptors for PAR.
Lysine residues are acceptor sites in PARP1
In contrast to the deletion of the BRCT domain, deletion
of the remaining amino acids in the AD of PARP1 (Ac,
aa 466–525) (Figure 6A), a region previously reported
to be acetylated (26), resulted in severely impaired auto-
modiﬁcation (Figure 6C) and reduced PAR formation
(Supplementary Figure 5B), suggesting that acceptor
sites are localized in this region of PARP1. As PAR
levels generated by PARP1 Ac were decreased but did
not drop completely, additional PAR acceptor sites are
likely to exist in other domains of PARP1. Trans-
poly(ADP-ribosyl)ation of diﬀerent fragments of PARP1
by wild-type PARP1 indeed conﬁrmed that not only the
AD but also a fragment containing amino acid 1–214 is
modiﬁed (Supplementary Figure 5C).
ADP-ribose has earlier been described to be a potent
histone glycation and glycoxidation agent in vitro, leading
to the formation of ketoamine glycation conjugates (30).
Table 1. Kinetic parameters of chimera PARP2-1
hPARP1a hPARP2-1
1–373
DNA
hPARP2-1
1–373
+DNA
hPARP2-1
+1–373
+DNA
hPARP2-1
+1–373
+DNA
Vmax (mmolmin1mg1) 0.2–2.4 NC NC 0.114 0.010 0.488 0.026
Km (mM) 59–278 NC NC 1111 127.7 140.8 19.72
Kcat (s
1) 0.41 NC NC 0.121 0.011 0.521 0.028
Kcat/Km (s
1mM1) 1.475–6.949 NC NC 0.109 0.022 3.696 0.715
NC: not calculable (product levels below detection limit).
aValues as reported in the literature.
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Figure 5. PARP1 forms a catalytic dimer which requires at least one functional FI and FIII domain for activity. (A) Domain organization of the
PARP1 deletion mutants used for this ﬁgure. (B) PAR formation by PARP1 when co-incubated with the indicated inactive proteins or fragments at a
molar ratio of 1:1 or 1:5. According to the manufacturer, the anti-PAR antibody LP96-10 cross reacts with bovine serum albumin (BSA) (band at
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When we analyzed the chemical linkage stability of auto-
modiﬁed PARP1, we found that it was stable up to pH
10 (but not at pH 13.5) and that incubation with 1M
hydroxylamine at pH 7 for 30min at 308C or 608C did
not release the modiﬁcation (Supplementary Figure 5D).
This observation suggests that the protein-ADP-ribose
linkage indeed might occur on lysines. To exclude that
the investigated auto-modiﬁcation of PARP1 was due
to traces of ADP-ribose within the provided NAD, the
inactive PARP1 mutant M890V/D899N was incubated
with radioactive NAD. Only upon long exposure a faint
labeling of PARP1 M890V/D899N was observed while
PARP1 E988K was able, as described earlier, to modify
itself (Supplementary Figure 5E), conﬁrming that the
observed auto-modiﬁcation of PARP1 was due to its enzy-
matic activity.
Next, we analyzed the trans-poly(ADP-ribosyl)ation of
a fragment comprising the AD (aa 373–525) of PARP1
by full-length PARP1. Although auto-modiﬁcation of
PARP1 was much more eﬃcient than trans-poly(ADP-
ribosyl)ation, speciﬁc labeling of the AD fragment was
observed (Figure 6D, second lane). In order to identify
individual lysine residues within the AD which serve as
acceptor sites for PAR, we analyzed trans-poly(ADP-ribo-
syl)ation of the AD fragment containing three lysine to
arginine substitutions (K498, K521 and K524, called
KTR). These sites were previously reported to be targets
for acetylation (26). Modiﬁcation of the 373–525 KTR
fragment by full-length PARP1 was reduced as compared
to 373–525wt (Figure 6D, third lane). Since trans-
poly(ADP-ribosyl)ation of a protein fragment might
lead, due to structural constrains, to unspeciﬁc modiﬁca-
tion of amino acids and might thus not be comparable
to modiﬁcation of the full-length protein, we generated a
full-length PARP1 mutant which contains the three lysine
to arginine substitutions at position 498, 521 and 524.
around 64 kDa). (C) PAR formation by DBD deletion mutants FI, FII and FIII. (D) PAR formation by a combination of the two DBD
deletion mutants FI and FIII. (E) PAR formation by the DBD deletion mutants FI and FIII when they were co-incubated with catalytically
inactive PARP1 mutants or with fragment 1–373. (F) PAR formation by PARP1 lacking the WGR domain. (G) PAR formation by PARP1 WGR
in combination with DBD deletion mutants, catalytically inactive PARP1 mutants or with fragment 1–373. Molecular size markers in kilo Daltons
and the border between stacking and separating gel (asterisk) are indicated.
Figure 6. Lysine residues within the AD of PARP1 are target sites for poly(ADP-ribosyl)ation. (A) Domain organization of the PARP1 mutants used
for this ﬁgure. (B) Auto-modiﬁcation of the indicated PARP1 mutants lacking either the BRCT domain (BRCT) or the BRCT domain and
carrying substitutions for all glutamic acid residues in the remaining stretch of the AD (BRCT/E). (C) Auto-modiﬁcation of a PARP1 deletion
mutant lacking aa 466–525 (Ac), a region that was previously shown to be acetylated. (D) Trans-poly(ADP-ribosyl)ation of the AD from amino
acid 373–525 by PARP1. KTR, K498/521/524R. (E) Auto-modiﬁcation of a PARP1 K498/521/524R mutant. Molecular size markers in kilo Daltons
are indicated.
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Importantly, this mutant showed strongly reduced auto-
modiﬁcation, very much comparable to the levels
observed for the PARP1 Ac mutant (Figure 6E).
Overall, these experiments provide evidence that not glu-
tamic acid residues but instead at least three lysine resi-
dues within the auto-modiﬁcation loop (aa 466–525)
and additional residues within the ﬁrst 214 amino acids
of PARP1 are target sites for enzymatic auto-ADP-
ribosylation.
DISCUSSION
In this study we analyzed the poly(ADP-ribosyl)ation
capacity of PARP1 and the closely related proteins
PARP2 and PARP3 under standardized reaction condi-
tions and investigated the molecular mechanism of PAR
formation. Human PARP1 and PARP2 were able to
auto-modify themselves and generate PAR, although to
diﬀerent levels. Neither polymer formation nor auto-
modiﬁcation was observed for PARP3 under the tested
conditions.
PARP1 deletion mutants and fusion proteins had been
successfully employed before to study diﬀerent aspects of
poly(ADP-ribosyl)ation (31,32). Here, we have generated
PARP family chimera to analyze the molecular mecha-
nism of PAR formation. The PARP chimera revealed
that the WGR/CAT domains of PARP1, PARP2 and
PARP3 tightly cooperate with their corresponding
amino-terminal domains. Closer examination of PARP1
revealed that FI, FIII and the WGR/CAT domain of
PARP1 are required and suﬃcient for PAR formation.
FII and the BRCT domain, however, were not essential
for the enzymatic activity. The DBD interacted directly
with the CAT domain of PARP1. DBD bound to DNA
increased Vmax and reduced the Km of the CAT for NAD.
We also provide evidence that PARP1 forms a catalytic
dimer in which lack of either FI or FIII could be func-
tionally complemented by a protein containing these
domains. Finally, we identiﬁed three lysine residues
within the AD and additionally the ﬁrst 214 amino acids
of the DBD as target sites for enzymatic covalent auto-
poly(ADP-ribosyl)ation by PARP1.
We employed three diﬀerent methods to assess
poly(ADP-ribosyl)ation. First, 3H-NAD at a concentra-
tion of 400 mM was used to measure TCA-precipitable
polymer formation in time course experiments. Second,
32P-NAD at a concentration of only 100 nM was used to
measure auto-modiﬁcation after short incubation periods
(10 s). This approach resulted in distinct bands corre-
sponding to the modiﬁed protein and most likely repre-
senting mono(ADP-ribosyl)ation or short oligomers of
ADP-ribose attached to the labeled protein. Third, unla-
beled NAD at a concentration of 400 mM was used to
measure PAR formation detected by western blot. The
anti-PAR antibody typically detected high molecular
weight polymers, most of which remained as a smear at
the top of the separating gel or even in the stacking gel.
This approach was not very suitable to make quantitative
statements but could be readily applied to analyze whether
a protein was active or not.
Human PARP3 was previously described by Augustin
et al. to be an active enzyme, as detected by autoradiogra-
phy after 15min incubation with 10 mM 32P-NAD (19).
Augustin and co-workers did not, however, compare the
activity of PARP3 to that of PARP1 or any other PARP
family member under these conditions. We analyzed
PARP3 in comparison to PARP1 and PARP2 under stan-
dardized reaction conditions and could not observe
any activity for this protein. However, when we applied
the conditions provided by Augustin et al. to measure
PARP3 activity by autoradiography, we could also
observe PARP3 auto-modiﬁcation (data not shown), sug-
gesting that the protein possesses some degree of activity
under certain well-deﬁned conditions. Further investiga-
tions are needed to analyze the extent of PAR formation
by PARP3 as well as its physiological relevance.
The DBD of PARP1 interacted in a coordinated
and DNA-dependent manner with the CAT domain of
PARP1, but not with that of PARP2 or PARP3. Thus,
despite the high level of structural similarity between the
CATs of PARP1, PARP2 and PARP3, these domains
cannot compensate for each other and may possess unan-
ticipated intrinsic regulatory functions. Since the PARP1
DBD is not or only partially present in other PARP family
members, the newly identiﬁed intra-molecular interaction
might provide a promising surface for the development of
PARP1 speciﬁc inhibitors.
In our study, several enzymatic dead mutants with
deletions in the DBD could be functionally complemented
by another inactive PARP1 mutant containing the missing
domain, thus implicating that PARP1 is forming a dimer
for poly(ADP-ribosyl)ation. The existence of catalytically
active protein dimers in which each monomer is lacking
a domain required for enzymatic activity was surprising
and suggests that PARP1 is a highly ﬂexible molecule
with rather loose domain architecture.
Consistent with earlier reports (33,34) our results
showed that zinc ﬁnger FI is absolutely required for the
DNA-dependent activation of the protein, whereas zinc
ﬁnger FII is dispensable. Zinc ﬁnger FII may, however,
determine the binding speciﬁcity for DNA single strand
breaks as suggested previously by Gradwohl et al. (35).
Our data revealed that the recently discovered zinc-
binding motif FIII is essential for the interaction of
the DBD with the CAT and thus also for the activation
of the enzyme. Furthermore, the so far uncharacterized
WGR domain is an indispensable prerequisite for PAR
formation, although this domain is not necessary for the
interaction between the DBD and the CAT.
The interaction between the DBD bound to DNA and
the CAT domain increased the maximum reaction velocity
Vmax by a factor of four and reduced the Km for NAD
roughly from 1mM to 140 mM (Table 1). The reaction
eﬃciency Kcat/Km was thereby increased by a factor of
more than 30. The total cellular NAD concentration was
previously estimated to be around 350 mM (36). Zhang
et al. argued that NAD cofactors should readily pass
through nuclear pores, which would suggest that cytoplas-
mic NAD levels reﬂect nuclear NAD concentrations (37).
The same group estimated the free nuclear NAD concen-
tration to be around 70 mM (38). Despite this uncertainty
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in the estimation of free nuclear NAD concentrations,
we believe that increasing the aﬃnity of PARP1 for
NAD by binding to DNA double strand breaks might
be an important regulatory step to allow PAR formation
at physiological NAD concentrations. Release of PARP1
from DNA would consequently reduce the aﬃnity
of PARP1 for NAD and terminate PAR formation.
Importantly, the nuclear concentration of NAD can be
modulated by NMN adenylyl transferase 1 (NMNAT-1),
which catalyzes the ﬁnal step of NAD biosynthesis. A
recent study revealed that NMNAT-1 is able to interact
with and stimulate PARP1 (39). It is thus tempting to
speculate that PARP1 activation by its binding to DNA
strand breaks is supported by the localized action of
NMNAT-1.
Our results suggest that activation of PARP1 occurs
in deﬁned sequential steps (Figure 7A). First, the DBD
binds to certain damages within the DNA. This
enhances the interaction between the DBD and the
CAT domain. As a consequence, minor structural rear-
rangements within the catalytic cleft occur, resulting in
an increased aﬃnity for NAD. Increasing substrate
aﬃnity and additionally substrate turnover rates then
allows for high reaction eﬃciency and very rapid auto-
modiﬁcation at distinct lysine residues followed by PAR
chain elongation. An analogous model can be envi-
sioned for the protein chimera PARP2-1, which is
activated by the PARP1 DBD in the presence of
double strand breaks mimicking DNA (Supplementary
Figure 6A).
Figure 7. Model for PARP1 activation and ADP-ribosylation of lysine residues. (A) Model for the sequential activation and regulation of PARP1.
The DNA-dependent interaction between the DBD and the WGR/CAT induces a state of high substrate aﬃnity and high turnover rate in PARP1.
Subsequently, acceptor amino acids in the auto-modiﬁcation loop as well as in the DBD are poly(ADP-ribosyl)ated. (B) Proposed reaction mech-
anism for NADase-dependent auto-ADP-ribosylation of lysine residues by PARP1 via Schiﬀ base formation. (C) Scheme depicting the identiﬁed
PAR acceptor lysine residues in PARP1. (D) A revised view of ADP-ribose metabolism. PARP1 catalyzes lysine mono(ADP-ribosyl)ation via
its NADase activity and subsequently PAR chain elongation. PARG cleaves glycosidic ribose–ribose bonds to generate PARP1-Lys-ADP-KA,
which is then substrate for an ADP-ribosyl protein lyase. See discussion for details. NAM, nicotinamide; Lys, lysine; ADP-KA, ADP-ketamine;
ADPR, ADP-ribose; ADP-DP, ADP-300-deoxypentose-200-ulose.
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The assumption that PARP1 is modiﬁed at glutamic
acid residues was based mainly on the chemical stability
of the ADP-ribose-PARP1 linkage, which was very heter-
ogeneous but in part of a similar type as carboxyl esters
in mono-ADP-riboslyated histones isolated from cells
(23). The presented mutation analysis studies revealed
that neither deletion of all glutamic acid residues in the
BRCT domain (aa 385–476, containing nine glutamic acid
residues) nor additional mutation of the remaining gluta-
mic acid residues to glutamine in the AD (aa 477–557,
containing eight glutamic acid residues) aﬀected auto-
modiﬁcation or PAR formation and thus provide strong
evidence that these amino acids in the AD are not the
acceptor sites for poly(ADP-ribosyl)ation. Interestingly,
mutation of the three lysines K498, K521 and K524 in
the AD of PARP1 to arginines strongly reduced the
auto-modiﬁcation of the enzyme, suggesting that these
residues in fact are acceptors for PAR. A longer exposure
of the gel revealed a weak labeling of PARP1 KTR (data
not shown) and it may well be that additional lysine resi-
dues serve as acceptor sites in this domain. Furthermore,
acceptor sites can also be expected in the DBD of PARP1.
Whether these sites are also lysine residues or whether
outside the AD other amino acids serve as PAR acceptors
is currently not known.
Modiﬁcation of proteins by ADP-ribose can be charac-
terized according to their chemical properties. ADP-ribo-
sylated lysine residues were described to be stable in the
presence of 1M hydroxylamine at pH 7, while chemically
modiﬁed glutamic and aspartic acid residues would rap-
idly release the ADP-ribose moiety (40,41). Our chemical
analysis of modiﬁed PARP1 revealed that the observed
linkage most likely corresponds to the glycation linkage
described above. Thus we propose that ADP-ribosylation
of PARP1 is catalyzed by its NADase activity, which sub-
sequently allows modiﬁcation of lysine residues positioned
close to the catalytic active site to Lys-ADP-ribose
ketamine (Figure 7B, C and D). This moiety could then
serve as acceptor for the elongation reaction, which is
catalyzed by glutamic acid residue E988 in human
PARP1. We are currently investigating whether other
ADP-ribose acceptor proteins are modiﬁed by PARP1 in
the same manner.
To date two enzymes, poly(ADP-ribose) glycohaydro-
lase (PARG) and ADP-ribosyl protein Lyase, have been
described to be involved in PAR catabolism (42,43). While
PARG possesses both exo- and endoglycosidic activities,
the Lyase was described to cleave the bond between pro-
teins and mono(ADP-ribose). ADP-ribosylation of lysines
creates a chemical bond, which is not a substrate for
PARG, which cleaves the ribose–ribose bonds. Breaking
a lysine-ADP-ribose linkage would instead require the
activity of a Lyase (Figure 7D). Alternatively, the last
ADP-ribose moieties might remain on PARP1 to serve
as elongation sites for the next round of PAR formation
or to mark the chromatin to memorize the location of
previous DNA damage repair.
Lysine residues K498, K521 and K524 were previously
identiﬁed as targets for acetylation by p300 and P300/
CBP-associated factor (PCAF) in a stimulus-dependent
manner (26). Remarkably, simple addition of PCAF
reduced poly(ADP-ribosyl)ation by PARP1 (unpublished
observation), suggesting that the interaction domain of
PARP1 with PCAF is overlapping with the ADP-ribose
acceptor sites. Furthermore, we recently showed that acet-
ylation of PARP-2 strongly reduced the enzymatic activity
(44). Already more than 20 years ago, a possible interre-
lation between poly(ADP-ribosyl)ation reactions and
post-translational protein acetylation had been discussed
(45,46). Our ﬁnding that acetylation of lysine residues
interferes with ADP-ribosylation supports this idea and
points at an interesting crosstalk between acetylation of
and ADP-ribosylation by PARP family members. This
crosstalk hypothesis is further strengthened by the ﬁnding
that the enzymatic activity of PARP1 is not required for
the function as transcriptional co-activator of NF-kB,
a role which requires acetylation of PARP1 (47).
During apoptosis, PARP-1 is cleaved by diﬀerent cas-
pases to generate 89-kDa and 24-kDa fragments, a well-
characterized hallmark of apoptosis. The data shown pro-
vide a functional explanation for the observed inactivation
of PARP1 upon caspase cleavage, as this cleavage is sepa-
rating FI and FII (aa 1–214) from FIII (aa 214–373), thus
no longer allowing the DBD to interact as an intact poly-
peptide with the CAT domain for subsequent activation.
Our chemical and mutational analyses provide evidence
that lysine residues are acceptor sites for auto-modiﬁca-
tion by PARP1 in vitro (Figure 6B). As PARP1 is the main
acceptor protein for poly(ADP-ribosyl)ation in vivo
(48,49), our ﬁndings are most likely also relevant in vivo.
Conﬁrming acceptor sites in vivo, however, is very diﬃcult
for diﬀerent reasons. First, mutations within the DBD
to eliminate the acceptor sites in this region and to allow
only the analysis of the three lysine residues in the auto-
modiﬁcation domain would aﬀect the activation of
PARP1 by DNA. Second, PARP1 is known to be mod-
iﬁed by PARP2 and possibly by other PARP family mem-
bers. Whether theses proteins are modifying PARP1 also
at the auto-modiﬁcation sites or at other residues is cur-
rently not known. In any case, however, this crosstalk
would interfere with in vivo analysis of PARP1 auto-
modiﬁcation.
In conclusion, we propose that PARP1 forms a catalytic
dimer that allows the interaction of the DNA-binding
domain with the CAT to modify distinct lysine residues
as ADP-ribose acceptor sites in the AD as well as addi-
tional acceptor sites in the DNA-binding domain. These
insights will allow further investigations to elucidate the
biological functions of PARP1 and its enzymatic activity.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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